Biomunex Announces Strategic Artificial Intelligence Collaboratio
Biomunex Announces Strategic Artificial Intelligence Collaboratio
Publish Date: 2026-05-26 09:33:00
Source Domain: natlawreview.com
- Biomunex Pharmaceuticals announced strategic collaborations with Gordion Bioscience and Tangramed Biotech to integrate AI into its R&D and accelerate next-generation immunotherapy development in oncology.
- The collaboration with Gordion Bioscience aims to identify novel bispecific target combinations for cancer therapy using computational target discovery and patient-derived biological network analysis.
- The partnership with Tangramed Biotech will leverage generative AI and multimodal target-combination discovery to identify therapeutic opportunities using Biomunex’s proprietary BiXAb® platforms.
- These collaborations aim to optimize target selection, shorten discovery timelines, and increase translational success in developing novel immunotherapies.
- Biomunex is also focused on implementing AI across other areas of the company to enhance operations beyond R&D, including finance, HR, and legal departments.
